ArticleFrontiers in molecular biosciences2026
HSF1 modulates lipid metabolism and ferroptosis in sarcopenia: a novel diagnostic biomarker and therapeutic target.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia, an age-correlated decline in skeletal muscle mass and function, has been increasingly linked to ferroptosis, which is an iron-dependent form of regulated cell death driven by lipid peroxidation. Nevertheless, the diagnostic potential and mechanistic role of ferroptosis-relevant genes (FRGs) in sarcopenia remains poorly understood. Methods: We integrated bioinformatics analyses and experimental validation to identify and characterize key FRGs in sarcopenia. By employing RNA-seq data from public datasets (GSE25941 and GSE9103), we identified differentially expressed FRGs and applied weighted gene co-expression network analysis (WGCNA) and multiple machine learning algorithms (comprising LASSO, SVM, KNN, XGBoost, and NNET) to screen for diagnostic biomarkers. Results: Six hub FRGs ( Conclusion: Our findings not only underscore the significance of FRGs in sarcopenia pathogenesis but also highlight their potential as diagnostic markers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.